How I treat the acquired von Willebrand syndrome Article Report uri icon

Overview

MeSH Major

  • Annexin A5
  • Antiphospholipid Syndrome
  • Syphilis

abstract

  • The acquired von Willebrand syndrome (AVWS) is a bleeding disorder that is frequently unrecognized or is misdiagnosed as von Willebrand disease. AVWS is characterized by structural or functional defects of von Willebrand factor (VWF) that are secondary to autoimmune, lymphoproliferative or myeloproliferative, malignant, cardiovascular, or other disorders. VWF abnormalities in these disorders can result from (1) antibody-mediated clearance or functional interference, (2) adsorption to surfaces of transformed cells or platelets, or (3) increased shear stress and subsequent proteolysis. Diagnosis can be challenging as no single test is usually sufficient to prove or exclude AVWS. Furthermore, there are no evidence-based guidelines for management. Treatments of the underlying medical condition, including chemo/radiotherapy, surgery, or immunosuppressants can result in remission of AVWS, but is not always feasible and successful. Because of the heterogeneous mechanisms of AVWS, more than one therapeutic approach is often required to treat acute bleeds and for prophylaxis during invasive procedures; the treatment options include, but are not limited to, desmopressin, VWF-containing concentrates, intravenous immunoglobulin, plasmapheresis or recombinant factor VIIa. Here, we review the management of AVWS with an overview on the currently available evidence and additional considerations for typical treatment situations. © 2011 by The American Society of Hematology.

publication date

  • June 23, 2011

Research

keywords

  • Report

Identity

Digital Object Identifier (DOI)

  • 10.1182/blood-2010-11-297580

PubMed ID

  • 21540459

Additional Document Info

start page

  • 6777

end page

  • 6785

volume

  • 117

number

  • 25